US2015368341A1PendingUtilityA1

Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

51
Assignee: ALEXION PHARMA INCPriority: Dec 8, 2000Filed: Feb 24, 2015Published: Dec 24, 2015
Est. expiryDec 8, 2020(expired)· nominal 20-yr term from priority
Inventors:Katherine S. BowdishAnke Kretz-Rommel
A61P 35/02C07K 2317/732A61P 43/00C07K 16/2803A61K 2039/505C07K 2317/24G01N 2333/70596A61P 37/04G01N 2800/52C07K 2317/76C07K 16/3061A61P 35/00C07K 2317/622A61K 47/6849C07K 2317/92G01N 33/57505
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Small animal models for assessing immunomodulatory effects of compounds are provided.

Claims

exact text as granted — not AI-modified
1 . A method for treating CLL comprising administering to a patient suffering from CLL an antibody, or an antigen-binding fragment thereof, that binds to OX-2/CD200 and comprises:
 (a) a light chain CDR1 having the sequence set forth in residues 26-36 of SEQ ID NO:208, a light chain CDR2 having the sequence set forth in residues 52-58 of SEQ ID NO:208, a light chain CDR3 having the sequence set forth in residues 91-99 of SEQ ID NO:208, a heavy chain CDR1 having the sequence set forth in SEQ ID NO:114, a heavy chain CDR2 having the sequence set forth in SEQ ID NO:165, and a heavy chain CDR3 having the sequence set forth in SEQ ID NO:189; (d1B5)   (b) a light chain CDR1 having the sequence set forth in residues 26-40 of SEQ ID NO:206; a light chain CDR2 having the sequence set forth in residues 56-62 of SEQ ID NO:206; a light chain CDR3 having the sequence set forth in residues 95-103 of SEQ ID NO:206; a heavy chain CDR1 having the sequence set forth in SEQ ID NO:141; a heavy chain CDR2 having the sequence set forth in residues 51-66 of SEQ ID NO:200; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO:188; (d1B10)   (c) a light chain CDR1 having the sequence set forth in residues 26-35 of SEQ ID NO:207; a light chain CDR2 having the sequence set forth in residues 51-57 of SEQ ID NO:207; a light chain CDR3 having the sequence set forth in residues 90-98 of SEQ ID NO:207; a heavy chain CDR1 having the sequence set forth in SEQ ID NO:111; a heavy chain CDR2 having the sequence set forth in SEQ ID NO:118; and a heavy chain CDR3 having the sequence set forth in residues 100-112 of SEQ ID NO:201; (d1A5)   (d) a light chain polypeptide comprising: a light chain CDR1 having the sequence set forth in residues 26-41 of SEQ ID NO:210; a light chain CDR2 having the sequence set forth in residues 57-63 of SEQ ID NO:210; a light chain CDR3 having the sequence set forth in residues 96-104 of SEQ ID NO:210; a heavy chain CDR1 having the sequence set forth in SEQ ID NO:140; a heavy chain CDR2 having the sequence set forth in SEQ ID NO:162; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO:187; (c1A10) or   (e) a light chain CDR1 having the sequence set forth in residues 26-37 of SEQ ID NO:211; a light chain CDR2 having the sequence set forth in residues 53-58 of SEQ ID NO:211; a light chain CDR3 having the sequence set forth in residues 92-102 of SEQ ID NO:211; a heavy chain CDR1 having the sequence set forth in SEQ ID NO:136; a heavy chain CDR2 having the sequence set forth in SEQ ID NO:159; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO:181, (c2aA10)   wherein the patient's CLL has been identified as overexpressing OX-2/CD200 three to six-fold as compared to normal peripheral blood mononuclear cells.   
     
     
         2 . The method of  claim 1 , wherein the antibody, or antigen-binding fragment of the antibody, comprises a light chain CDR1 having the sequence set forth in residues 26-36 of SEQ ID NO:208, a light chain CDR2 having the sequence set forth in residues 52-58 of SEQ ID NO:208, a light chain CDR3 having the sequence set forth in residues 91-99 of SEQ ID NO:208, a heavy chain CDR1 having the sequence set forth in SEQ ID NO:114, a heavy chain CDR2 having the sequence set forth in SEQ ID NO:165, and a heavy chain CDR3 having the sequence set forth in SEQ ID NO:189. 
     
     
         3 . The method of  claim 1 , wherein the antibody, or antigen-binding fragment of the antibody, comprises a light chain CDR1 having the sequence set forth in residues 26-40 of SEQ ID NO:206; a light chain CDR2 having the sequence set forth in residues 56-62 of SEQ ID NO:206; a light chain CDR3 having the sequence set forth in residues 95-103 of SEQ ID NO:206; a heavy chain CDR1 having the sequence set forth in SEQ ID NO:141; a heavy chain CDR2 having the sequence set forth in residues 51-66 of SEQ ID NO:200; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO:188. 
     
     
         4 . The method of  claim 1 , wherein the antibody, or antigen-binding fragment of the antibody, comprises a light chain CDR1 having the sequence set forth in residues 26-35 of SEQ ID NO:207; a light chain CDR2 having the sequence set forth in residues 51-57 of SEQ ID NO:207; a light chain CDR3 having the sequence set forth in residues 90-98 of SEQ ID NO:207; a heavy chain CDR1 having the sequence set forth in SEQ ID NO:111; a heavy chain CDR2 having the sequence set forth in SEQ ID NO:118; and a heavy chain CDR3 having the sequence set forth in residues 100-112 of SEQ ID NO:201. 
     
     
         5 . The method of  claim 1 , wherein the antibody, or antigen-binding fragment of the antibody, comprises a light chain polypeptide comprising: a light chain CDR1 having the sequence set forth in residues 26-41 of SEQ ID NO:210; a light chain CDR2 having the sequence set forth in residues 57-63 of SEQ ID NO:210; a light chain CDR3 having the sequence set forth in residues 96-104 of SEQ ID NO:210; a heavy chain CDR1 having the sequence set forth in SEQ ID NO:140; a heavy chain CDR2 having the sequence set forth in SEQ ID NO:162; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO:187. 
     
     
         6 . The method of  claim 1 , wherein the antibody, or antigen-binding fragment of the antibody, comprises a light chain CDR1 having the sequence set forth in residues 26-37 of SEQ ID NO:211; a light chain CDR2 having the sequence set forth in residues 53-58 of SEQ ID NO:211; a light chain CDR3 having the sequence set forth in residues 92-102 of SEQ ID NO:211; a heavy chain CDR1 having the sequence set forth in SEQ ID NO:136; a heavy chain CDR2 having the sequence set forth in SEQ ID NO:159; and a heavy chain CDR3 having the sequence set forth in SEQ ID NO:181. 
     
     
         7 . The method of  claim 1 , wherein said antibody, or antigen-binding fragment thereof, is selected from the group consisting of a monoclonal antibody, a chimeric antibody, an Fv, an scFv, a Fab′, and an F(ab′) 2 . 
     
     
         8 . The method of  claim 1 , wherein the antibody, or antigen-binding fragment thereof, is humanized.

Join the waitlist — get patent alerts

Track US2015368341A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.